Literature DB >> 26824431

Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis.

Richard Holman1, John K Olynyk1,2,3, Hemant Kulkarni4, Paolo Ferrari5,6.   

Abstract

BACKGROUND: Parenteral iron is integral in the treatment of anaemia of chronic kidney disease patients on haemodialysis (HD). However, increased liver iron concentration (LIC) can result from such treatment, and this correlates poorly with serum ferritin or transferrin saturation values. It is unclear whether increased cardiac iron concentration also occurs in this setting. We aimed to evaluate the relationship of intravenous iron supplementation to hepatic and cardiac iron deposition in chronic HD subjects.
METHODS: A cohort of 10 patients on chronic HD for at least 1 year underwent MRI-based quantitation of hepatic and cardiac iron content to evaluate the relationship between intravenous iron supplements and hepatic and cardiac iron deposition. The results were compared against the cumulative parenteral iron dose and serum iron markers.
RESULTS: The median age was 61 years (95% confidence interval (CI) 50-71), HD time 2.5 years (95%CI 2.0-5.3) and cumulative iron dose 4300 mg (95%CI 2110-9045). Hepatic iron concentration was elevated in eight of 10 subjects (median 46 mmol/kg, range 31-76). Cardiac iron levels were within the reference range in all subjects. There was poor correlation between conventional haematinic values and either LIC or cardiac iron levels. None of the study subjects exhibited elevated cardiac iron concentration.
CONCLUSION: Whilst HD patients receiving standard parenteral iron therapy have elevated LICs, this is not associated with cardiac iron deposition. Transferrin saturation and serum ferritin levels are poor markers of either liver or cardiac iron deposition in HD subjects.
© 2016 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  MRI; chronic kidney disease; ferritin; heart; iron; liver

Mesh:

Substances:

Year:  2017        PMID: 26824431     DOI: 10.1111/nep.12735

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  5 in total

1.  The prevalence of cardiac and hepatic iron overload in patients with kidney failure: A protocol for systematic review and meta-analysis.

Authors:  Abdulqadir J Nashwan; Mohamed A Yassin; Alaa Abd-Alrazaq; Farag Shuweihdi; Hanan F Abdul Rahim; Mujahed Shraim
Journal:  Health Sci Rep       Date:  2022-06-08

Review 2.  Characterizing Cardiac Involvement in Chronic Kidney Disease Using CMR-a Systematic Review.

Authors:  Kenneth Mangion; Kirsty McDowell; Patrick B Mark; Elaine Rutherford
Journal:  Curr Cardiovasc Imaging Rep       Date:  2018-01-31

Review 3.  Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents.

Authors:  Jose Portolés; Leyre Martín; José Jesús Broseta; Aleix Cases
Journal:  Front Med (Lausanne)       Date:  2021-03-26

4.  INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis-a protocol for a prospective open-label blinded endpoint randomised controlled trial.

Authors:  Sandawana William Majoni; Jane Nelson; Darren Germaine; Libby Hoppo; Stephanie Long; Shilpa Divakaran; Brandon Turner; Jessica Graham; Sajiv Cherian; Basant Pawar; Geetha Rathnayake; Bianca Heron; Louise Maple-Brown; Robert Batey; Peter Morris; Jane Davies; David Kiran Fernandes; Madhivanan Sundaram; Asanga Abeyaratne; Yun Hui Sheryl Wong; Paul D Lawton; Sean Taylor; Federica Barzi; Alan Cass
Journal:  Trials       Date:  2021-12-02       Impact factor: 2.279

Review 5.  Iron Overload in Chronic Kidney Disease: Less Ferritin, More T2*MRI.

Authors:  Abdulqadir J Nashwan; Mohamed A Yassin; Mohamed Izham Mohamed Ibrahim; Hanan F Abdul Rahim; Mujahed Shraim
Journal:  Front Med (Lausanne)       Date:  2022-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.